ESTONIAN STATE AGENCY OF MEDICINES LATVIAN FOOD AND VETERINARY SERVICE LITHUANIAN NATIONAL FOOD AND VETERINARY RISK ASSESSMENT INSTITUTE

Similar documents
CMD(v) ANNOTATED QRD TEMPLATE. MRP/DCP adapted version based on version 7 of 8/2005

Review of Legislation for Veterinary Medicinal Products Version 2

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

[Version 7.2, 12/2008] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

LABELLING AND PACKAGE LEAFLET A. LABELLING

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS VIRBAGEN OMEGA - EN 1

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

LABELLING AND PACKAGE LEAFLET

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY of PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/18

GUIDELINES ON LABELLING OF STOCK REMEDIES IN SOUTH AFRICA. Issued by the Registrar: Act No. 36 of 1947, Private Bag X343, Pretoria 0001

United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS DECENTRALISED PROCEDURE

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/12

Committee on the Environment, Public Health and Food Safety

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

GUIDELINE ON LABELLING OF STOCK REMEDIES

Error! Reference source not found. I. SUMMARY OF PRODUCT CHARACTERISTICS

ANNEXES. to the Proposal. for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL

SUMMARY OF PRODUCT CHARACTERISTICS

Vetoquinol/DOLPAC Small dogs/european Renewal June 2011 SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Amoxicillin trihydrate. Amoxicillin trihydrate. Amoxicillin trihydrate. Amoxicillin trihydrate. Amoxicillin trihydrate. Amoxicillin trihydrate

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Hymatil 300 mg/ml solution for injection for cattle and sheep Tilmicosin

Guideline on quality data requirements for veterinary medicinal products intended for minor use or minor species (MUMS)/limited market

[Version 8.1,01/2017] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Vetrisulf powder for oral solution for chickens, turkeys and geese

Legislation, Registration and Control Procedures for Veterinary Medicinal Products in the European Union

[Version 8, 10/2012] SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX III LABELLING AND PACKAGE LEAFLET

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY of PRODUCT CHARACTERISTICS (SPC)

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

I.3. Central competent authority. Local competent authority I.6. I.12. I.16. Entry BIP in EU. I.17. No(s) of CITES. I.22. Number of packages

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Withdrawal period: 93 days Milk: Not authorised for use in animals producing milk for human consumption.

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

4.5. Special precautions for use Special precautions to be taken by person administering the veterinary medicinal product to animals

B. PACKAGE LEAFLET 1

Council of the European Union Brussels, 17 September 2014 (OR. en) Mr Uwe CORSEPIUS, Secretary-General of the Council of the European Union

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Standard operating procedure

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Legislation on Veterinary Medicinal Products (VMPs) and legal status of relevant VMPs for anesthesia of finfish

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

PROFESSIONAL PRACTICE STANDARD

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Enrotab 50 mg tablets for dogs

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

Public Assessment Report Scientific discussion. Amlodipin Accord (amlodipine besilate)

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/33

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS DECENTRALISED PROCEDURE

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

Veterinary Medicinal Product

Council of the European Union Brussels, 15 September 2014 (OR. en) Mr Uwe CORSEPIUS, Secretary-General of the Council of the European Union

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC FOR ANTIMICROBIAL PRODUCTS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Irish Medicines Board

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS MUTUAL RECOGNITION PROCEDURE

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Irish Medicines Board

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

DIRECTIVE 2001/82/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 6 November 2001 on the Community code relating to veterinary medicinal products

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Zubrin EN 1/42

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Scientific Discussion post-authorisation update for Rheumocam extension X/007

Company: Richter Pharma AG MUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

LUTEOSYL(d)-Cloprostenol mg/ml Solution for injection for cattle and pigs

MUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Irish Medicines Board

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Indicated for the treatment of pruritus associated with allergic dermatitis and the clinical manifestations of atopic dermatitis in dogs.

PRESS RELEASE COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

ANNEX Part 1 Model animal health certificate for imports into the Union of dogs, cats and ferrets COUNTRY:

Transcription:

ESTONIAN STATE AGENCY OF MEDICINES LATVIAN FOOD AND VETERINARY SERVICE LITHUANIAN NATIONAL FOOD AND VETERINARY RISK ASSESSMENT INSTITUTE GUIDELINE ON COMMON BALTIC PACKAGE FOR VETERINARY MEDICINAL PRODUCTS Introduction The national competent authorities (NCAs) for veterinary medicinal products in the three Baltic States have agreed to publish this document to assist Applicants / Marketing Authorisation Holders in creating common Baltic packages for veterinary medicinal products. While the NCAs are committed to assist Applicants and Marketing Authorisation Holders in their goal to achieve common Baltic packages for their products, it must be emphasised that labelling cannot be reduced or abbreviated to such an extent that safety is compromised. This guideline is applicable for veterinary medicinal products undergoing an authorisation procedure or authorised via national procedure, decentralised procedure (DCP) or mutual recognition procedure (MRP). The NCAs will update this document as needed. What is a common Baltic package of a veterinary medicinal product? There is no legal definition of a Baltic package. Traditionally, Baltic refers to the three Baltic States Estonia, Latvia and Lithuania. As each of the Baltic States is often considered to be a small market or a very small market, the pharmaceutical industry has expressed its interest in the manufacturing of trilingual Baltic packages. In practice the term Baltic package usually refers to trilingual (EE/LV/LT) package used for at least one component of the packaging material (carton, label, blister, combined labellingpackage leaflet) of veterinary medicinal product. However this guideline shall also apply to bilingual packages, when only 2 out of 3 Baltic States (e.g. LV/LT or EE/LV) are involved. It should be noted that Baltic package does not prevent the combination of a Baltic country and a non-baltic country, should the marketing authorisation holder so prefer. Legal basis Directive 2001/82/EC, as amended, lays down the basic rules concerning labelling. Each of the Baltic States has implemented the relevant legislation and follows relevant EU guidelines, including QRD template. Therefore, there are basically the same rules concerning labelling in all three Baltic States, except package 'blue-box' requirements and additional information on labelling/package leaflet that may be required or permitted nationally (relevant document is available on CMDv website). Conditions/requirements to be met A common (bilingual/trilingual) Baltic package can be obtained only if the particulars of the approved labelling text (including combined labelling-package leaflet) are the same in all languages covered by the package. Package blue box requirements that apply in certain Baltic States do not prevent the printing of Baltic package. Any other differences in the labelling text (including combined labelling-package leaflet) should be notified simultaneously to all NCAs involved in the future package. Harmonised labelling may be obtained via common Baltic Package Procedure for Veterinary Medicinal Products. However in certain cases submission of variation may be requested. Furthermore, the multilingual package is only possible if the readability is not compromised by adding 2 or more languages to the labelling elements, e.g. too small font size. If Baltic package is planned for new products (DCP/MRP), Applicants should ensure that common product name is proposed for all concerned countries. Any issues related to the name should be solved during the MA procedure (preferably by Day 106 in DCP and Day 65 in MRP), in order to avoid variation. Besides, Applicants should be convinced that it would be possible to display all particulars of

the proposed labelling text in all languages on the multilingual package. It is recommended that Applicants only propose labelling text which is required by the annotated QRD template. The omission of some particulars of labelling text should be justified. The shortened text will be evaluated and approved during DC/MR procedure. The template for presentation of labelling text to appear on the outer and/or immediate Baltic package is provided below (Annex 1). This template does not replace or supersede the requirements laid down in the annotated QRD template, but provides additional guidance that should be followed in case of common (bilingual/trilingual) Baltic package. Furthermore some of this additional guidance allows saving space, which may be compromised by placing information in two or three different languages. Guidance text applicable to Baltic package only is indicated in blue colour.

PARTICULARS TO APPEAR ON <THE OUTER PACKAGE> <AND> <THE IMMEDIATE PACKAGE> {NATURE/TYPE} Annex 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Name, strength (if applicable) and pharmaceutical form of the veterinary medicinal product, as well as target species (if applicable), should be expressed identically in all languages. For fixed-combination products: The names of the active substances should be presented separated by a /, unless agreed differently during MR/DC procedure. In case of space limitation name(s) of active substance(s) to appear under the name of the veterinary medicinal product may be stated in Latin (when Estonia is involved) or English (when Estonia is not involved) without any brackets or further explanations. Combination of Latin/English name(s) with national ones should be avoided. In case of space limitation internationally agreed units might be used without translation (decided on a case by case basis). 2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES Composition of the veterinary medicinal product should be expressed identically in all languages. In case of space limitation name(s) of active substance(s) and, where applicable, excipients may be stated in Latin (when Estonia is involved) or English (when Estonia is not involved), except for the outer package of OTC products. 3. PHARMACEUTICAL FORM 4. PACKAGE SIZE 5. TARGET SPECIES 6. INDICATION(S) 7. METHOD AND ROUTE(S) OF ADMINISTRATION 8. WITHDRAWAL PERIOD 9. SPECIAL WARNING(S), IF NECESSARY 10. EXPIRY DATE

In case of space limitation the abbreviation EXP may be used to replace national terms. EXP should not be used in combination with national terms. For immediate package only: It is also acceptable, if expiry date is stated without any 11. SPECIAL STORAGE CONDITIONS 12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY 13. THE WORDS FOR ANIMAL TREATMENT ONLY AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE For immediate package only: In case of space limitation Latin term Ad us. vet. may be used to replace national terms (decided on a case by case basis). Ad us. vet. should not be used in combination with national terms. 14. THE WORDS KEEP OUT OF THE SIGHT AND REACH OF CHILDREN 15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER The name of the country should be in the national languages. 16. MARKETING AUTHORISATION NUMBER(S) 17. MANUFACTURER S BATCH NUMBER In case of space limitation the abbreviation Lot may be used to replace national terms. Lot should not be used in combination with national terms. For immediate package only: It is also acceptable, if batch number is stated without any

MINIMUM PARTICULARS TO SMALL IMMEDIATE PACKAGING UNITS {NATURE/TYPE} 1. NAME OF THE VETERINARY MEDICINAL PRODUCT In case of space limitation name of active substance to appear under the name of the veterinary medicinal product may be in Latin (when Estonia is involved) or English (when Estonia is not involved) without any brackets or further explanations. Combination of Latin/English name(s) with national ones should be avoided. 2. QUANTITY OF THE ACTIVE SUBSTANCE(S) In case of space limitation name(s) of active substance(s) may be stated in Latin (when Estonia is involved) or English (when Estonia is not involved. Combination of Latin/English name(s) with national ones should be avoided. 3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES 4. ROUTE(S) OF ADMINISTRATION 5. WITHDRAWAL PERIOD 6. BATCH NUMBER In case of space limitation the abbreviation Lot may be used to replace national terms. Lot should not be used in combination with national terms. It is also acceptable, if batch number is stated without any 7. EXPIRY DATE In case of space limitation the abbreviation EXP may be used to replace national terms. EXP should not be used in combination with national terms. It is also acceptable, if expiry date is stated without any 8. THE WORDS FOR ANIMAL TREATMENT ONLY In case of space limitation Latin term Ad us. vet. may be used to replace national terms (decided on a case by case basis). Ad us. vet. should not be used in combination with national terms.

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS {NATURE/TYPE} 1. NAME OF THE VETERINARY MEDICINAL PRODUCT In case of space limitation name of active substance to appear under the name of the veterinary medicinal product may be in Latin (when Estonia is involved) or English (when Estonia is not involved) without any brackets or further explanations. Combination of Latin/English name(s) with national ones should be avoided. 2. NAME OF THE MARKETING AUTHORISATION HOLDER 3. EXPIRY DATE In case of space limitation the abbreviation EXP may be used to replace national terms. EXP should not be used in combination with national terms. It is also acceptable, if expiry date is stated without any 4. BATCH NUMBER In case of space limitation the abbreviation Lot may be used to replace national terms. Lot should not be used in combination with national terms. It is also acceptable, if batch number is stated without any 5. THE WORDS FOR ANIMAL TREATMENT ONLY In case of space limitation Latin term Ad us. vet. may be used to replace national terms (decided on a case by case basis). Ad us. vet. should not be used in combination with national terms.